ZA201805403B - Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor - Google Patents

Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor

Info

Publication number
ZA201805403B
ZA201805403B ZA2018/05403A ZA201805403A ZA201805403B ZA 201805403 B ZA201805403 B ZA 201805403B ZA 2018/05403 A ZA2018/05403 A ZA 2018/05403A ZA 201805403 A ZA201805403 A ZA 201805403A ZA 201805403 B ZA201805403 B ZA 201805403B
Authority
ZA
South Africa
Prior art keywords
inhibitor
hyperlipidemia
administering
methods
combination
Prior art date
Application number
ZA2018/05403A
Other languages
English (en)
Inventor
Viktoria Gusarova
Jesper Gromada
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ZA201805403B publication Critical patent/ZA201805403B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2018/05403A 2016-03-03 2018-08-14 Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor ZA201805403B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302907P 2016-03-03 2016-03-03
PCT/US2017/020221 WO2017151783A1 (en) 2016-03-03 2017-03-01 Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor

Publications (1)

Publication Number Publication Date
ZA201805403B true ZA201805403B (en) 2019-08-28

Family

ID=58361088

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/05403A ZA201805403B (en) 2016-03-03 2018-08-14 Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor

Country Status (13)

Country Link
US (2) US20170253666A1 (cg-RX-API-DMAC7.html)
EP (1) EP3423157A1 (cg-RX-API-DMAC7.html)
JP (3) JP7541810B2 (cg-RX-API-DMAC7.html)
KR (1) KR102456731B1 (cg-RX-API-DMAC7.html)
CN (1) CN109069868B (cg-RX-API-DMAC7.html)
AU (1) AU2017227713B2 (cg-RX-API-DMAC7.html)
CA (1) CA3016764A1 (cg-RX-API-DMAC7.html)
EA (1) EA201891979A1 (cg-RX-API-DMAC7.html)
IL (1) IL261420A (cg-RX-API-DMAC7.html)
MA (1) MA43734A (cg-RX-API-DMAC7.html)
MX (1) MX2018010401A (cg-RX-API-DMAC7.html)
WO (1) WO2017151783A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805403B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
WO2017151783A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
AU2017258105B2 (en) * 2016-04-28 2024-09-05 Regeneron Pharmaceuticals, Inc. Methods for treating patients with familial hypercholesterolemia
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
CA3188213A1 (en) * 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor
WO2022187353A1 (en) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
WO2025185644A1 (zh) * 2024-03-05 2025-09-12 江苏恒瑞医药股份有限公司 抗angptl3抗体治疗高血脂症的用途及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
DE60041246D1 (de) 1999-02-12 2009-02-12 Harvard College Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CA2440355C (en) 2001-02-22 2011-03-08 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
EP1451578B1 (en) 2001-11-16 2013-08-21 Genentech, Inc. Use of angptl3 antagonists for the treatment of liver diseases
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
KR101503937B1 (ko) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
JP5711671B2 (ja) 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
EA023073B1 (ru) 2009-07-14 2016-04-29 Дзе Скриппс Рисёч Инститьют Способы и композиции для лечения или предупреждения артрита или повреждения сустава
CA2786071C (en) 2010-01-08 2021-01-12 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP3444348A1 (en) 2011-06-21 2019-02-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
RU2015119547A (ru) 2012-10-25 2016-12-20 МЕДИММЬЮН, ЭлЭлСи Стабильный низковязкий состав с антителом
ES2753381T3 (es) 2013-03-14 2020-04-08 Uab Research Foundation Miméticos de apolipoproteína y usos de los mismos
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EA201592267A1 (ru) 2013-06-07 2016-04-29 Ридженерон Фармасьютикалз, Инк. Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
CA2930069A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20170037409A1 (en) 2013-12-24 2017-02-09 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AU2015252895B2 (en) 2014-05-01 2021-07-15 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
AU2015289617B2 (en) 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
IL260931B2 (en) 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
WO2017151783A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
CN109789194B (zh) 2016-04-08 2022-08-02 瑞泽恩制药公司 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法
AU2017258105B2 (en) 2016-04-28 2024-09-05 Regeneron Pharmaceuticals, Inc. Methods for treating patients with familial hypercholesterolemia
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US20200369760A1 (en) 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CA3188213A1 (en) 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor

Also Published As

Publication number Publication date
CN109069868B (zh) 2023-06-06
JP2022078306A (ja) 2022-05-24
IL261420A (en) 2018-10-31
AU2017227713B2 (en) 2022-12-22
US12281173B2 (en) 2025-04-22
US20170253666A1 (en) 2017-09-07
JP7541810B2 (ja) 2024-08-29
US20200199253A1 (en) 2020-06-25
CA3016764A1 (en) 2017-09-08
EA201891979A1 (ru) 2019-01-31
AU2017227713A1 (en) 2018-09-13
JP2019512472A (ja) 2019-05-16
KR20180118181A (ko) 2018-10-30
KR102456731B1 (ko) 2022-10-24
MA43734A (fr) 2018-11-28
WO2017151783A1 (en) 2017-09-08
JP2024059787A (ja) 2024-05-01
CN109069868A (zh) 2018-12-21
MX2018010401A (es) 2019-03-06
EP3423157A1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
IL261420A (en) Methods for treating clients with hyperlipidemia by adding a pcsk9 blocker in combination with an angpt3 blocker
IL262130A (en) Methods for treating excess fat in the blood using angptl8 inhibitor and angptl3 inhibitor
IL271212A (en) Methods for treating excess blood fat in diabetic patients by administering a pcsk9 inhibitor
ZA201806557B (en) Methods for treating patients with familial hypercholesterolemia
SG10202005298RA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
ZA201701578B (en) Combination therapy for treating a paramyxovirus
GB201522398D0 (en) Device for photodynamic therapy
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
SG11201610333VA (en) Combination therapy with glutaminase inhibitors
PL3371165T3 (pl) Inhibitor btk do zastosowania w terapii rakowej
PL3169353T3 (pl) SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
ZA201507450B (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
HUE065176T2 (hu) Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
PL3157548T3 (pl) Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
PL3390448T3 (pl) Terapia dopęcherzowa raka pęcherza moczowego
GB201821147D0 (en) Mirna for use in therapy
HK1261754A1 (en) Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
PT3167881T (pt) Etamsilato administrado localmente como medicamento
IL256336A (en) Device for laser and/or LED treatment
HK40027567A (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
HK1262072A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
HK1232804A1 (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
IL250080A0 (en) Treatment methods for patients with familial heterozygous hypercholesterolemia
GB201611017D0 (en) Therapeutic treatments
GB201611016D0 (en) Therapeutic treatments